Bank of New York Mellon Corp Has $81,000 Holdings in OptiNose, Inc. (NASDAQ:OPTN)

Bank of New York Mellon Corp lessened its position in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,178 shares of the company's stock after selling 170,507 shares during the period. Bank of New York Mellon Corp owned approximately 0.12% of OptiNose worth $81,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. State Street Corp grew its position in OptiNose by 14.2% in the third quarter. State Street Corp now owns 341,303 shares of the company's stock worth $229,000 after buying an additional 42,500 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of OptiNose by 33.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company's stock worth $870,000 after acquiring an additional 326,918 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of OptiNose by 3.2% in the 3rd quarter. FMR LLC now owns 16,541,849 shares of the company's stock worth $11,083,000 after acquiring an additional 518,610 shares during the last quarter. Institutional investors and hedge funds own 85.60% of the company's stock.

Insider Activity

In related news, CEO Ramy A. Mahmoud sold 6,376 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total transaction of $33,729.04. Following the transaction, the chief executive officer now owns 126,931 shares of the company's stock, valued at approximately $671,464.99. This trade represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 8,213 shares of company stock worth $43,643 in the last three months. 2.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on OPTN shares. HC Wainwright reaffirmed a "neutral" rating and set a $9.00 target price (down from $18.00) on shares of OptiNose in a report on Friday, March 21st. Piper Sandler reaffirmed a "neutral" rating and set a $9.00 price objective (down from $15.00) on shares of OptiNose in a research note on Friday, March 21st. Finally, Lake Street Capital lowered OptiNose from a "buy" rating to a "hold" rating and reduced their target price for the company from $17.00 to $9.00 in a report on Thursday, March 20th.

OptiNose Price Performance

OptiNose stock traded down $0.02 during trading hours on Thursday, hitting $9.14. The company had a trading volume of 70,447 shares, compared to its average volume of 63,812. The firm's fifty day moving average is $6.50 and its 200-day moving average is $7.85. The firm has a market capitalization of $92.06 million, a P/E ratio of -2.18 and a beta of -0.88. OptiNose, Inc. has a fifty-two week low of $4.82 and a fifty-two week high of $21.15.

OptiNose (NASDAQ:OPTN - Get Free Report) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.67. The firm had revenue of $21.47 million for the quarter, compared to analysts' expectations of $21.02 million. Analysts anticipate that OptiNose, Inc. will post -3.22 earnings per share for the current year.

OptiNose Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.